StockData
Amgen Inc logo

Amgen Inc (AMGN) stock

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3023% above fair value
$443.89−14.04 (-3.07%)

Close on Nov 18, 2026Market cap $239.98BP/E 25.7Yield 2.18%

Amgen net income

Net income is the profit left for shareholders after every expense, interest and tax.

Amgen's net income for the twelve months ending Sep 30, 2026 was $9.39B, up 34.1% year over year. For fiscal 2025 it was $7.71B, up 88.5% from the year before. Over ten years it grew 1.1% a year on average. The highest annual figure on record is $8.39B in fiscal 2018.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$7.71B+88.5%
FY2024Dec 31, 2024$4.09B-39.1%
FY2023Dec 31, 2023$6.72B+2.5%
FY2022Dec 31, 2022$6.55B+11.2%
FY2021Dec 31, 2021$5.89B-18.9%
FY2020Dec 31, 2020$7.26B-7.4%
FY2019Dec 31, 2019$7.84B-6.6%
FY2018Dec 31, 2018$8.39B+324.2%
FY2017Dec 31, 2017$1.98B-74.4%
FY2016Dec 31, 2016$7.72B+11.3%
FY2015Dec 31, 2015$6.94B+34.5%
FY2014Dec 31, 2014$5.16B+1.5%
FY2013Dec 31, 2013$5.08B+16.9%
FY2012Dec 31, 2012$4.35B+18.0%
FY2011Dec 31, 2011$3.68B-20.4%
FY2010Dec 31, 2010$4.63B+0.5%
FY2009Dec 31, 2009$4.61B+13.6%
FY2008Dec 31, 2008$4.05B+31.6%
FY2007Dec 31, 2007$3.08B–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$3.86B+20.1%
Q2 FY2026Jun 30, 2026$2.38B+65.9%
Q1 FY2026Mar 31, 2026$1.82B+5.1%
Q4 FY2025Dec 31, 2025$1.33B+112.6%
Q3 FY2025Sep 30, 2025$3.22B+13.6%
Q2 FY2025Jun 30, 2025$1.43B+92.0%
Q1 FY2025Mar 31, 2025$1.73B–
Q4 FY2024Dec 31, 2024$627.00M-18.3%
Q3 FY2024Sep 30, 2024$2.83B+63.6%
Q2 FY2024Jun 30, 2024$746.00M-45.9%
Q1 FY2024Mar 31, 2024-$113.00M-104.0%
Q4 FY2023Dec 31, 2023$767.00M-52.5%
Q3 FY2023Sep 30, 2023$1.73B-19.3%
Q2 FY2023Jun 30, 2023$1.38B+4.7%
Q1 FY2023Mar 31, 2023$2.84B+92.5%
Q4 FY2022Dec 31, 2022$1.62B-14.9%
Q3 FY2022Sep 30, 2022$2.14B+30.2%
Q2 FY2022Jun 30, 2022$1.32B-18.5%
Q1 FY2022Mar 31, 2022$1.48B-27.0%
Q4 FY2021Dec 31, 2021$1.90B+5.3%
Q1 FY2021Mar 31, 2021$1.65B-9.8%
Q4 FY2020Dec 31, 2020$1.62B-25.9%
Q3 FY2020Sep 30, 2020$2.02B+1.5%
Q2 FY2020Jun 30, 2020$1.80B-6.5%
Q1 FY2020Mar 31, 2020$1.83B-1.8%
Q2 FY2019Jun 30, 2019$2.18B-5.1%
Q1 FY2019Mar 31, 2019$1.99B-13.8%
Q4 FY2018Dec 31, 2018$1.93B–
Q3 FY2018Sep 30, 2018$1.86B-8.0%
Q2 FY2018Jun 30, 2018$2.30B+6.7%
Q1 FY2018Mar 31, 2018$2.31B+11.6%
Q4 FY2017Dec 31, 2017-$4.26B-320.4%
Q3 FY2017Sep 30, 2017$2.02B+0.2%
Q2 FY2017Jun 30, 2017$2.15B+15.0%
Q1 FY2017Mar 31, 2017$2.07B–
Q4 FY2016Dec 31, 2016$1.94B–
Q3 FY2016Sep 30, 2016$2.02B–
Q2 FY2016Jun 30, 2016$1.87B–

More Amgen figures

See a number that looks wrong?